Puromycin Aminonucleoside, also known as PAN, NSC3056, is useful in the study of human glomerular disease, and glomerular function and morphology. PAN is used to probe endothelial glycosaminoglycan synthesis in cultured glomerular endothelial cells and their relation to cell permeability.PAN treatment increased oxidative stress level of podocytes significantly with the induction of Nox4. Puromycin aminonucleoside increases podocyte permeability by modulating ZO-1 in an oxidative stress-dependent manner.

[1] Ha TS, Park HY, Seong SB, Ahn HY. Puromycin aminonucleoside increases podocyte permeability by modulating ZO-1 in an oxidative stress-dependent manner. Exp Cell Res. 2016 Jan 1;340(1):139-49. doi: 10.1016/j.yexcr.2015.12.001. PubMed PMID: 26683996.

[2]  Kang YL, Saleem MA, Chan KW, Yung BY, Law HK. The cytoprotective role of autophagy in puromycin aminonucleoside treated human podocytes. Biochem Biophys Res Commun. 2014 Jan 10;443(2):628-34. doi: 10.1016/j.bbrc.2013.12.015. PubMed PMID: 24333414.

[3] Xie H, Lin HL, Wang N, Sun YL, Kan Y, Guo H, Chen JL, Fang M. Inhibition of microRNA-30a prevents puromycin aminonucleoside-induced podocytic apoptosis by upregulating the glucocorticoid receptor α. Mol Med Rep. 2015 Oct;12(4):6043-52. doi: 10.3892/mmr.2015.4226. PubMed PMID: 26299668.

[4] Xia L, et al. Podocyte-specific expression of organic cation transporter PMAT: implication in puromycin aminonucleosidenephrotoxicity. Am J Physiol Renal Physiol. 2009 Jun;296(6):F1307-13.